MAPT and Alzheimer disease: Originally developed for research purposes, these criteria introduced three key imaging biomarkers for AD diagnosis: amyloid-β plaques (A) assessed through amyloid positron emission tomography (PET), fibrillar tau (T) evaluated via tau PET, and neurodegeneration (N) detected using 18F-fluorodeoxyglucose (FDG) PET or magnetic resonance imaging (MRI).1